SG11201707240SA - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations - Google Patents

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Info

Publication number
SG11201707240SA
SG11201707240SA SG11201707240SA SG11201707240SA SG11201707240SA SG 11201707240S A SG11201707240S A SG 11201707240SA SG 11201707240S A SG11201707240S A SG 11201707240SA SG 11201707240S A SG11201707240S A SG 11201707240SA SG 11201707240S A SG11201707240S A SG 11201707240SA
Authority
SG
Singapore
Prior art keywords
dihydroimidazo
quinazoline
substituted
containing combinations
combinations
Prior art date
Application number
SG11201707240SA
Inventor
Ningshu Liu
Carol Pena
Michael Jeffers
Isabelle Genvresse
Original Assignee
Bayer Pharma AG
Bayer Healthcare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Healthcare Pharmaceuticals Inc filed Critical Bayer Pharma AG
Publication of SG11201707240SA publication Critical patent/SG11201707240SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201707240SA 2015-03-09 2016-03-07 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations SG11201707240SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130418P 2015-03-09 2015-03-09
PCT/EP2016/054727 WO2016142312A1 (en) 2015-03-09 2016-03-07 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
SG11201707240SA true SG11201707240SA (en) 2017-10-30

Family

ID=55538186

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707240SA SG11201707240SA (en) 2015-03-09 2016-03-07 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Country Status (15)

Country Link
US (1) US10406162B2 (en)
EP (1) EP3268490B1 (en)
JP (1) JP6867295B2 (en)
KR (1) KR20180013851A (en)
CN (1) CN107864625B (en)
AU (1) AU2016231259A1 (en)
BR (1) BR112017019188A2 (en)
CA (1) CA2978830A1 (en)
EA (1) EA201791974A1 (en)
IL (1) IL254167A0 (en)
MX (1) MX2017011635A (en)
PH (1) PH12017501643A1 (en)
SG (1) SG11201707240SA (en)
SV (1) SV2017005530A (en)
WO (1) WO2016142312A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CU24400B1 (en) 2013-04-08 2019-04-04 Bayer Pharma AG A COMPOSITION THAT INCLUDES 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
BR112018012914B1 (en) 2015-12-22 2023-04-18 SHY Therapeutics LLC COMPOUND, USE OF A COMPOUND AND PHARMACEUTICAL COMPOSITION
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
EP3515911A1 (en) 2016-09-23 2019-07-31 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
IL271230B1 (en) 2017-06-21 2024-02-01 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3670513B1 (en) * 2017-08-15 2023-09-20 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Fgfr inhibitor and medical application thereof
WO2019105734A1 (en) * 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
CN111500587A (en) * 2020-04-15 2020-08-07 湖南省科域生物医药科技有限公司 Application of PGR (platelet-rich protein) as product for treating endometriosis and PGR detection kit

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790266B2 (en) 2002-09-30 2011-10-12 バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト Condensed azolepyrimidine derivatives
AR064106A1 (en) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS
EP2244721A4 (en) 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2558126A2 (en) * 2010-04-16 2013-02-20 Bayer Intellectual Property GmbH Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
JO3733B1 (en) 2011-04-05 2021-01-31 Bayer Ip Gmbh Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2850836A1 (en) * 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
UY34484A (en) * 2011-12-15 2013-07-31 Bayer Ip Gmbh BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES
CU24400B1 (en) 2013-04-08 2019-04-04 Bayer Pharma AG A COMPOSITION THAT INCLUDES 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS
EP3003377A1 (en) * 2013-05-31 2016-04-13 Novartis AG Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
CN105934256B (en) 2013-12-03 2019-12-27 拜耳制药股份公司 PI3K inhibitor combination
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP2018512403A (en) 2015-03-09 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト Use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines
US20190382839A1 (en) 2016-02-01 2019-12-19 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
TN2018000271A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
CN113382997A (en) * 2019-01-31 2021-09-10 拜耳股份有限公司 Monohydrate of hydrochloric acid Rogatinib and solid state thereof

Also Published As

Publication number Publication date
WO2016142312A1 (en) 2016-09-15
IL254167A0 (en) 2017-10-31
CN107864625A (en) 2018-03-30
US10406162B2 (en) 2019-09-10
SV2017005530A (en) 2018-10-02
KR20180013851A (en) 2018-02-07
JP2018510869A (en) 2018-04-19
EP3268490A1 (en) 2018-01-17
EA201791974A1 (en) 2018-05-31
MX2017011635A (en) 2018-02-09
CA2978830A1 (en) 2016-09-15
AU2016231259A1 (en) 2017-09-21
EP3268490B1 (en) 2020-07-08
CN107864625B (en) 2021-05-28
JP6867295B2 (en) 2021-04-28
US20180055851A1 (en) 2018-03-01
BR112017019188A2 (en) 2018-04-24
PH12017501643A1 (en) 2018-03-12

Similar Documents

Publication Publication Date Title
IL254167A0 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
HK1244804A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL252053A0 (en) תרכובות מותמרות של פירזולו(1, 5-a)פירימידינים ושימוש שלהן בטיפול בהפרעות רפואיות
IL250823A0 (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
HK1250645A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HRP20190013T1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
HK1223921A1 (en) New octahydro-cyclobuta [1,2-c;3,4-c]dipyrrol-2-yl -[12-c34-c]-2
HK1256614A1 (en) Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds
EP3452481A4 (en) SUBSTITUTED IMIDAZO[1,2-b
EP3380475A4 (en) OCTAHYDROPYRROLO [3, 4-c
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
HUE043108T2 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
EP3281678A4 (en) Ball
EP3265469A4 (en) New synthetic methods
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
TH1601002954A (en) New Octahydro-Cyclobuta[1,2-c;3,4-c']dipyrrole-2-yl
GB201512405D0 (en) The Golf Thermo-Pod
GB201516063D0 (en) The microsecurity
GB201517026D0 (en) Bb 2015
AU2015902928A0 (en) New synthetic methods
AU2015901901A0 (en) The ball retriever
GB201509551D0 (en) Cordials